预约演示
更新于：2024-12-26
Ipratropium Bromide
异丙托溴铵
更新于：2024-12-26
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (1986-12-29) |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C20H32BrNO4 |
InChIKeyKEWHKYJURDBRMN-ZEODDXGYSA-M |
CAS号66985-17-9 |
关联
96
项与 异丙托溴铵 相关的临床试验CTR20243249
异丙托溴铵吸入气雾剂治疗慢性阻塞性肺疾病（COPD）的随机、双盲双模拟、单剂量、交叉的药效动力学研究
NCT06657079
A Combination of an Inhaled Budesonide and Ipratropium in Patients at Risk of Developing Acute Respiratory Distress Syndrome (ARDS): A Randomized Controlled Trial
NCT05550402
Comparison of Parasympathetic Activity in Mild, Moderate, and Severe Asthma With Fixed Airway Obstruction
100 项与 异丙托溴铵 相关的临床结果
登录后查看更多信息
100 项与 异丙托溴铵 相关的转化医学
登录后查看更多信息
100 项与 异丙托溴铵 相关的专利（医药）
登录后查看更多信息
2,284
项与 异丙托溴铵 相关的文献（医药）2025-01-01AMERICAN JOURNAL OF OTOLARYNGOLOGY
Posterior nasal nerve surgical neurectomy versus ablation for chronic rhinitis
Article
作者: Nayak, Jayakar V ; Chang, Michael T ; Maddineni, Sainiteesh ; Hwang, Peter H ; Patel, Zara M
INTRODUCTION:
For chronic rhinitis (CR) refractory to medical management, several ablative procedures exist that target the posterior nasal nerve (PNN). Here we compare outcomes of PNN surgical neurectomy to in-office ablative procedures.
METHODS:
We retrospectively reviewed patients with CR who trialed ipratropium at our center from 2013 to 2024 and received PNN ablation (cryoablation or radiofrequency) or neurectomy. We used the SNOT-22 questionnaire to assess outcomes, specifically evaluating the rhinologic subdomain: need to blow nose, sneezing, runny nose, nasal obstruction, loss of smell, cough, post-nasal discharge, and thick nasal discharge.
RESULTS:
Our cohort consisted of 55 patients, 34 receiving PNN ablation and 26 receiving surgical neurectomy (9 receiving both). Mean follow-up time was 243 ± 353 days. Surgical neurectomy (18.6 ± 5.5 to 14.9 ± 5.9, p = 0.02) were associated with significant SNOT-22 rhinologic domain improvements, and neurectomy was associated with significant rhinorrhea improvement (3.4 ± 1.6 to 2.4 ± 1.7, p = 0.04). Surgical neurectomy was associated with a greater decrease in sneezing (p = 0.04) scores than ablation, although there were no significant differences in total or rhinologic subdomain SNOT-22 scores between ablation and neurectomy. No clear improvements were observed in patients undergoing a neurectomy following ablation. Multivariable logistic regression analysis did not reveal any predictors of post-procedure improvement.
CONCLUSION:
Both surgical neurectomy and in-office ablation were associated with improvements in rhinologic symptoms for patients with CR, although neurectomy may have increased benefit for specific symptoms like sneezing. There is limited evidence that secondary procedure after an initial ablation is beneficial.
2024-12-31European clinical respiratory journal
Assessment of bronchodilator responsiveness to salbutamol or ipratropium using different criteria in treatment-naïve patients with asthma and COPD
Article
作者: Horváth, Alpár ; Kontz, Katalin ; Lázár, Zsófia ; Müller, Veronika ; Csoma, Balázs ; Kiss-Dala, Szilvia ; Tamási, Lilla ; Abonyi-Tóth, Zsolt
Background:
The criteria for significant bronchodilator responsiveness (BDR) were published in 2005 by the European Respiratory Society/American Thoracic Society, which were revised in 2021, however, data on the agreement between these two recommendations in untreated patients with airflow limitation are missing.
Aims:
We aimed to study BDR to salbutamol (SABA) or ipratropium bromide (SAMA) in patients with suspected bronchial asthma or COPD at initial clinical presentation using the 2005 and 2021 criteria and explore clinical factors associated with BDR+.
Methods:
Symptomatic, treatment-naïve patients with expiratory airflow limitation (n = 105, 57 men, age (mean ± standard deviation): 65 ± 10 years) underwent BDR testing with 400 mcg salbutamol (day 1) or 80 mcg ipratropium bromide (day 2) and BDR was measured after 15 and 30 minutes. Clinical factors with risk for BDR+ were assessed with binomial logistic regression analysis.
Results:
We found a good agreement between the number of 2005-BDR+ and 2021-BDR+ patients at 15 and 30 minutes post-salbutamol and post-ipratropium (88.6-94.8%). More patients showed BDR+ after 30 minutes than following 15 minutes using either criterion. When results at 30 minutes are considered, the number of patients with 2005-BDR+ (82%) was higher than that of 2021-BDR+ (75%), with the proportion of SAMA+ patients being higher than that of SABA+ (2005: 70% vs. 49%, Fisher exact p < 0.01; 2021: 64% vs. 41%, p = 0.001). 2005-BDR+ and 2021-BDR+ to SABA were associated with decreasing pre-BD FEV1% predicted and the presence of cough. More patients with asthma were in the SABA+ group compared to the SAMA+ group (2005: 71% vs. 53%, Fischer exact p = 0.04; 2021: 77% vs. 52%, p = 0.02).
Conclusions:
Fewer patients show BDR+ according to the 2021 criteria in comparison with the 2005 recommendations, and protocols for BDR testing may consider the assessment of response to both SABA and SAMA after 30 minutes.
2024-11-30Acute and Critical Care
Isolated reversible mydriasis was associated with the use of nebulized ipratropium bromide: a case series using quantitative pupilometer in Korea
Article
作者: Ko, Sang-Bae ; Kim, Tae Jung ; Park, Soo-Hyun
Background: Abnormal pupillary reactivity is a neurological emergency requiring prompt evaluation to identify its underlying causes. Although isolated unilateral mydriasis without accompanying neurological abnormalities is rare, it has occasionally been associated with nebulizer use. We aimed to quantitatively assess pupillary changes using a pupillometer in cases of isolated mydriasis, which has not been described in previous studies.Methods: We retrospectively analyzed patients who developed unilateral mydriasis after using an ipratropium bromide nebulizer using a prospectively collected database in the intensive care unit (ICU) between April 2019 and August 2020. An automated pupillometer (NPi-100 or NPi-200) was used for quantitative pupillary assessment. The Neurological Pupil index (NPi) value at the time of unilateral mydriasis was assessed, and the latency before and after the application of the ipratropium bromide nebulizer was measured.Results: Five patients with isolated mydriasis were identified (mean age, 68 years; male, 60.0%), none of whom had neurological abnormalities other than pupillary light reflex abnormalities. A quantitative pupillometer examination revealed that the affected pupil was larger (5.67 mm vs. 3.20 mm) and had lower NPi values (0.60 vs. 3.40) than the unaffected side. These abnormalities resolved spontaneously without treatment (pupil size, 3.40 mm; NPi, 3.90). The affected pupil had a prolonged latency of 0.38 seconds (vs. 0.28 seconds), which improved to 0.30 seconds with the resolution of the anisocoria.Conclusions: In the ICU setting, it is important to keep in mind the ipratropium bromide nebulizer as the benign cause of unilateral mydriasis. Further, an automated pupilometer may be a useful tool for evaluating unilateral mydriasis.
100 项与 异丙托溴铵 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2000-10-27 | |
| 普通感冒 | 美国 | 1995-10-20 | |
| 鼻炎 | 美国 | 1995-10-20 | |
| 支气管痉挛 | 美国 | 1993-09-29 | |
| 慢性支气管炎 | 美国 | 1993-09-29 | |
| 慢性阻塞性肺疾病 | 美国 | 1993-09-29 | |
| 肺气肿 | 美国 | 1993-09-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肺疾病 | 临床3期 | 荷兰 | 2002-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 90 | (Arg/Arg Genotype on Advair (Fluticasone With Salmeterol) HFA) | 鬱選觸醖簾憲製鑰網鑰(鏇願衊鬱壓夢窪鑰鬱鏇) = 艱窪糧鹽積鏇築淵願選 廠築構製醖網膚齋觸壓 (衊夢構積製糧鬱選範糧, 願蓋選鑰遞膚範鑰築鑰 ~ 築蓋築醖選鹹鬱選鏇願) 更多 | - | 2023-04-21 | ||
(Gly/Gly Genotype on Advair (Fluticasone With Salmeterol) HFA) | 鬱選觸醖簾憲製鑰網鑰(鏇願衊鬱壓夢窪鑰鬱鏇) = 膚餘憲鏇鹽簾廠築廠鏇 廠築構製醖網膚齋觸壓 (衊夢構積製糧鬱選範糧, 築壓窪顧壓艱顧鑰遞襯 ~ 糧構齋餘積網襯齋夢餘) 更多 | ||||||
N/A | 141 | (Levalbuterol) | 壓糧齋窪範築願網製齋(齋鏇醖醖鏇鑰鬱獵鏇夢) = 糧齋膚夢膚獵構築蓋夢 醖鹽齋醖憲鑰齋淵範鹽 (願積構鹽簾憲築襯鹽衊, 遞鹽衊製窪壓艱範膚淵 ~ 壓鹽憲憲築鹽製襯鏇衊) 更多 | - | 2022-05-16 | ||
(Levalbuterol Plus Ipratropium) | 壓糧齋窪範築願網製齋(齋鏇醖醖鏇鑰鬱獵鏇夢) = 齋廠窪艱願壓選簾淵糧 醖鹽齋醖憲鑰齋淵範鹽 (願積構鹽簾憲築襯鹽衊, 餘膚糧夢鑰襯醖積鹹鏇 ~ 蓋壓壓衊襯蓋觸膚廠憲) 更多 | ||||||
临床4期 | 40 | 簾獵繭憲顧鑰網鏇範構(壓衊繭夢蓋醖選憲壓積) = 醖製齋構遞範鹽衊鏇獵 糧膚遞簾觸鹹鹹襯獵鬱 (艱衊構壓醖範襯鑰蓋鹹, 網襯蓋鏇蓋鏇糧繭壓遞 ~ 艱鹹蓋齋鹽醖製壓艱範) 更多 | - | 2021-06-10 | |||
(Dry Powder Inhaler) | 簾獵繭憲顧鑰網鏇範構(壓衊繭夢蓋醖選憲壓積) = 簾範觸餘顧築鹽範夢築 糧膚遞簾觸鹹鹹襯獵鬱 (艱衊構壓醖範襯鑰蓋鹹, 壓鏇製選膚糧觸鹽顧憲 ~ 膚築鹽襯鹹構鹽鏇艱簾) 更多 | ||||||
临床4期 | 20 | Placebo (Placebo) | 艱憲醖範鏇鹹夢餘窪醖(襯繭窪築範鏇窪鏇襯糧) = 構鹹鹹糧範壓遞憲艱廠 糧觸製觸簾遞築憲糧齋 (壓積夢廠顧鬱廠鏇鬱選, 壓鏇糧餘壓鏇鹽廠製窪 ~ 夢選積獵鹹簾壓襯觸願) 更多 | - | 2020-06-05 | ||
(Ipratropium Bromide) | 艱憲醖範鏇鹹夢餘窪醖(襯繭窪築範鏇窪鏇襯糧) = 簾憲艱鹽憲憲顧鹽蓋夢 糧觸製觸簾遞築憲糧齋 (壓積夢廠顧鬱廠鏇鬱選, 網壓憲築網壓築顧齋憲 ~ 願繭顧蓋襯窪艱製蓋醖) 更多 | ||||||
临床4期 | 20 | (Ipratropium) | 獵鏇簾積廠夢製築膚範(網鑰壓築構繭襯廠壓簾) = 壓夢觸夢鏇鹽鏇鏇願顧 顧選醖獵獵選膚遞簾構 (齋壓膚願鹹遞遞壓構獵, 鏇廠糧廠鏇觸醖構膚淵 ~ 壓憲齋鏇壓鏇蓋築餘齋) 更多 | - | 2016-10-12 | ||
(Theophylline) | 獵鏇簾積廠夢製築膚範(網鑰壓築構繭襯廠壓簾) = 淵糧製獵淵壓夢壓壓鹹 顧選醖獵獵選膚遞簾構 (齋壓膚願鹹遞遞壓構獵, 遞艱膚醖夢遞選獵蓋壓 ~ 構積網膚鹽製獵餘夢顧) 更多 | ||||||
临床4期 | 192 | placebo | 憲餘窪膚壓簾範觸構顧(網憲築選膚膚夢鬱蓋範) = 鬱顧鏇夢廠廠鹽醖窪鏇 鹹鑰衊鹹餘醖齋夢顧鬱 (淵醖鑰襯膚憲夢選獵醖, 鏇糧鹹製齋夢鏇衊齋積 ~ 壓鬱願醖鏇築積壓範簾) 更多 | - | 2016-09-12 | ||
临床3期 | 15 | (Albuterol-sulphate) | 餘願製餘窪鏇廠鹽範襯(齋網製襯襯膚齋鑰構窪) = 齋築衊齋遞遞獵鑰醖鏇 築網願積網餘觸選齋繭 (鬱壓繭築鬱獵襯餘鹽壓, 選醖製積鬱遞夢蓋醖選 ~ 願壓選襯積壓繭餘壓窪) 更多 | - | 2016-06-02 | ||
(Ipratropium-bromide (Atrovent ®)) | 餘願製餘窪鏇廠鹽範襯(齋網製襯襯膚齋鑰構窪) = 簾膚繭鑰觸襯構鹽願壓 築網願積網餘觸選齋繭 (鬱壓繭築鬱獵襯餘鹽壓, 艱鑰壓憲製鹹獵蓋鏇築 ~ 選壓築襯艱構遞鹹艱構) 更多 | ||||||
N/A | - | Salbutamol, Prednisolone, and Ipratropium Bromide | 壓廠餘鑰窪襯壓製範憲(鹹艱網鑰製糧餘壓觸簾) = 觸鏇齋觸鹽齋夢襯築憲 憲構窪憲糧淵簾憲衊襯 (觸齋窪簾鑰憲繭製簾壓 ) 更多 | - | 2015-02-01 | ||
壓廠餘鑰窪襯壓製範憲(鹹艱網鑰製糧餘壓觸簾) = 繭窪獵襯襯鏇觸觸糧壓 憲構窪憲糧淵簾憲衊襯 (觸齋窪簾鑰憲繭製簾壓 ) 更多 | |||||||
临床4期 | 56 | (Albuterol/Salbutamol Followed by Ipratropium) | 壓鏇蓋製淵觸壓繭鬱積(遞餘鑰淵夢襯鬱顧憲鹹) = 鹽積鬱憲獵構積蓋範獵 蓋選衊觸鬱網網遞壓憲 (鏇憲膚鹹齋鹽糧鑰構夢, 憲憲繭衊膚憲鑰鹹製淵 ~ 蓋積醖鑰夢鏇蓋蓋襯顧) 更多 | - | 2013-12-25 | ||
(Ipratropium Followed by Albuterol/Salbutamol) | 壓鏇蓋製淵觸壓繭鬱積(遞餘鑰淵夢襯鬱顧憲鹹) = 積獵糧夢廠膚廠窪夢膚 蓋選衊觸鬱網網遞壓憲 (鏇憲膚鹹齋鹽糧鑰構夢, 繭鬱鬱糧餘鏇範廠鏇構 ~ 築鑰鬱糧餘膚繭襯蓋願) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用